ND0612

Phase 3Small molecule

NNeuroDerm Ltd.

ND0612 is one of 34 small molecule programs targeting Parkinson's Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson's DiseaseWithdrawn

Parkinson's DiseasePhase 3

Withdrawn

Competition

Competitive Landscape

50 competitors in Parkinson's Disease

#DrugCompanyPhaseTrials

Bendopa

MMerz North America, Inc.

Approved

13 2

Dayvigo

Eisai

Approved

1 3

Ingrezza

Neurocrine Biosciences

Hytrin

3 5

Strattera

MMap77

Phase 3

3 6

Glucophage

EMD Serono

Phase 3

2 7

Micardis

Boehringer Ingelheim

Phase 3

1 8

Ketalar

AAultman Health Foundation

Phase 2

2 9

Coreg

Akero Therapeutics

Phase 2

2 10

ABBV-951

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Parkinson's Disease

NCT02726386

Clinical

Trials by Indication[1]

Parkinson's Disease4 trials

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

Completed·NNeuroDerm Ltd.·Phase 2·NCT02577523·38 enrolled

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Withdrawn·NNeuroDerm Ltd.·Phase 3·NCT02782481

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

Active, not recruiting·NNeuroDerm Ltd.·Phase 2·NCT02726386·214 enrolled

Show 1 more trial

A Phase IIa Multicenter, Randomized, Double-blind, Placebo-controlled Study Followed by an Open-label Period, to Evaluate the Safety, Tolerability, and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Subcutaneous ND0612

Completed·NNeuroDerm Ltd.·Phase 2·NCT01883505·30 enrolled

Levodopa1 trial

Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

Completed·NNeuroDerm Ltd.·Phase 1·NCT01486628·36 enrolled

Female1 trial

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

Completed·NNeuroDerm Ltd.·Phase 1·NCT02604914·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for ND0612. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ND0612 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ND0612. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NeuroDerm Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNeuroDerm Ltd.

ND0612

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Parkinson's Disease4 trials

Levodopa1 trial

Female1 trial

References

Drug Info

Quick Facts

Related News